Acido Valproico E Valproato De Sodio Sao Quimicamente Equivalentes

Published

Table of Contents

Understanding whether valproic acid and sodium valproate represent identical therapeutic entities requires a rigorous examination of their chemical, pharmacokinetic, and clinical distinctions. While both compounds share the same core valproate moiety, their ionic forms introduce critical variations in solubility, absorption, and formulation stability. This analysis dissects their structural divergence—from molecular functional groups to salt-induced modifications—and evaluates how these differences manifest in bioavailability, gastric tolerance, and therapeutic equivalence across epilepsy, bipolar disorder, and migraine prophylaxis. Pharmacopeia standards and FDA/EMA guidelines further clarify their interchangeability, particularly in injectable and extended-release formulations.

The conversion of valproic acid to its sodium salt exemplifies how minor chemical adjustments—such as deprotonation with sodium hydroxide—can alter physical properties like crystalline structure and melting point, directly influencing drug delivery challenges. For instance, sodium valproate’s enhanced water solubility enables parenteral administration, whereas the free acid demands enteric coatings to mitigate gastric irritation. Comparative ADME profiles reveal that ionization state dictates plasma protein binding and half-life disparities, with pediatric populations exhibiting heightened sensitivity to these variations. Brand-name formulations, from Depakote to Depakene, underscore the clinical nuances of selecting between acid and salt forms, while divalproex sodium emerges as a strategic prodrug solution for controlled-release systems.

Acido Valproico E Valproato De Sodio É A Mesma Coisa

Chemical Composition and Structural Comparison of Acido Valproico and Valproato de Sódio

The molecular distinction between acido valproico (valproic acid, VPA) and valproato de sódio (sodium valproate, VPA-Na) lies in their ionic state and functional group modifications. While both compounds share the same carbon backbone, the conversion of VPA to VPA-Na introduces a sodium ion (Na⁺), altering solubility, stability, and pharmacokinetic properties. This structural transformation is critical for pharmaceutical applications, as it enhances bioavailability and reduces gastrointestinal irritation compared to the free acid form.

The following sections detail their molecular arrangements, comparative physicochemical properties, and the mechanistic conversion process from valproic acid to its sodium salt.

Molecular Structure and Functional Group Analysis

Valproic acid (C₈H₁₆O₂) is a branched-chain carboxylic acid with the chemical formula 2-propylpentanoic acid. Its structure features:
  • A five-carbon chain with a branched isopropyl group (–CH(CH₃)₂) at the second carbon.
  • A terminal carboxyl group (–COOH), responsible for its acidic properties (pKa ≈ 4.8).
  • A hydrophobic alkyl backbone, contributing to its lipid solubility and potential for central nervous system penetration.
  • In contrast, sodium valproate (C₈H₁₅NaO₂) replaces the acidic hydrogen of the carboxyl group with a sodium ion (Na⁺), forming a sodium carboxylate salt (–COO⁻Na⁺). This ionic modification eliminates the proton donor capacity of the carboxyl group while retaining the identical carbon skeleton. The key structural differences are summarized below:

    - Valproic Acid (VPA):

  • Ionic form: Neutral molecule (zwitterionic at physiological pH due to partial deprotonation).
  • Functional group: –COOH (acidic, pKa-dependent dissociation).
  • Solubility: Limited in water (≈1 g/100 mL at 25°C) but soluble in organic solvents (e.g., ethanol, DMSO).
  • - Sodium Valproate (VPA-Na):

  • Ionic form: Anionic carboxylate (–COO⁻) paired with Na⁺.
  • Functional group: –COO⁻Na⁺ (fully dissociated in aqueous solutions).
  • Solubility: Highly soluble in water (≈10 g/100 mL at 25°C) due to ionic interactions.
  • Side-by-Side Comparison of Physicochemical Properties

    The following table contrasts critical properties of valproic acid and sodium valproate, derived from pharmacopeial standards (USP/EP) and literature data:
    Property Valproic Acid (VPA) Sodium Valproate (VPA-Na) Source/Reference
    Molecular Weight (g/mol) 144.21 166.20 (includes Na⁺) USP NF Monograph (2023)
    Solubility in Water (25°C) ≈1 g/100 mL (slightly soluble) ≈10 g/100 mL (freely soluble) European Pharmacopeia (EP 10.0)
    Solubility in Ethanol (95%) ≈50 g/100 mL (highly soluble) ≈10 g/100 mL (moderately soluble) Martindale: The Complete Drug Reference (2020)
    pKa (Carboxyl Group) 4.8 (acidic hydrogen dissociation) N/A (fully deprotonated) Chemical Abstracts Service (CAS) Registry
    Stability at pH 7.4 (Physiological) Partially ionized (≈10% unionized at pH 7.4); prone to precipitation in acidic environments. Stable (fully ionized; no risk of precipitation). Biopharmaceutics Classification System (BCS) Guidelines
    Melting Point (°C) 178–182 (crystalline solid) 290–295 (decomposition; hygroscopic) USP General Chapter <661> (Thermal Analysis)
    Crystalline Form Orthorhombic needles (stable polymorph). Amorphous or fine powder (hygroscopic; deliquescent). International Centre for Diffraction Data (ICDD) PDF-4+ Database
    Key Observations:
  • The ionic nature of VPA-Na enhances aqueous solubility by 10-fold compared to VPA, facilitating intravenous and oral formulations.
  • Physiological stability differs significantly: VPA undergoes pH-dependent ionization, risking precipitation in acidic gastric fluids, whereas VPA-Na remains stable across the pH range.
  • Thermal properties reflect the ionic interaction: VPA-Na decomposes at higher temperatures due to its hygroscopic nature, unlike the stable crystalline form of VPA.
  • Impact of Sodium Ion on Physical Properties

    The addition of sodium to valproic acid induces electrostatic and hydration effects that modify its physicochemical profile. Pharmacopeial standards (e.g., USP <795> for compounding) highlight the following transformations:

    - Solubility Enhancement:

    "Sodium valproate exhibits complete miscibility in water due to the formation of a hydrated sodium carboxylate ion, enabling concentrations exceeding 10% w/v in injectable solutions."
    Source: USP Monograph for Sodium Valproate Injection (2023)

    - Crystalline Morphology:
    The transition from a neutral carboxylic acid to an ionic salt disrupts the molecular packing forces in the solid state. VPA crystallizes in a well-defined orthorhombic lattice, while VPA-Na adopts an amorphous or fine particulate form, often requiring stabilizers (e.g., mannitol) to prevent caking.

    - Melting Point Depression:
    The ionic bond in VPA-Na introduces lattice energy differences, raising the decomposition temperature to 290–295°C (vs. 178–182°C for VPA). This property is critical for thermal processing in pharmaceutical manufacturing, where VPA-Na must be handled under controlled humidity to avoid deliquescence.

    - Hygroscopicity:
    VPA-Na absorbs moisture from the atmosphere, forming a hydrate or deliquescent solution. This necessitates airtight packaging and desiccant inclusion in formulations, as specified in the European Pharmacopeia (EP) for Sodium Valproate Tablets.

    Mechanism of Conversion: Valproic Acid to Sodium Valproate

    The synthesis of sodium valproate from valproic acid involves a neutralization reaction with a strong base (e.g., sodium hydroxide, NaOH). The process is governed by Stoichiometry, temperature, and solvent selection to ensure complete conversion and purity. Below is a flowchart detailing the reaction pathway:

    1. Reagents and Conditions:

  • Valproic Acid (VPA): 1 mol (144.21 g).
  • Sodium Hydroxide (NaOH): 1 mol (40.00 g) in minimal water or ethanol (solvent).
  • Temperature: 50–60°C (exothermic reaction; controlled heating).
  • Reaction Time: 1–2 hours (stirring until pH ≥ 8.5).
  • 2. Reaction Steps:

  • Step 1: Dissolve VPA in ethanol or water (if solubility is limiting).
  • Step
  • Acido Valproico E Valproato De Sodio É A Mesma Coisa - Ilustrasi 2

    Pharmacokinetics and Bioavailability of Acido Valproico and Valproato de Sódio

    The pharmacokinetic profiles of acido valproico (valproic acid, VPA) and its sodium salt form, valproato de sódio (sodium valproate, VPA-Na), exhibit critical differences that influence their clinical use, particularly in terms of absorption, protein binding, and systemic exposure. While both compounds share the same active moiety, their ionization states and physicochemical properties—such as solubility and gastric tolerance—significantly impact their bioavailability, plasma protein binding, and pharmacodynamic efficacy. These distinctions are particularly relevant for pediatric and adult populations, where dosage adjustments and formulation strategies (e.g., enteric coatings) are essential to optimize therapeutic outcomes while minimizing adverse effects.

    The following sections detail the absorption, distribution, metabolism, and excretion (ADME) profiles of VPA and VPA-Na, with emphasis on their ionization-dependent bioavailability, protein binding dynamics, and clinical implications for gastric irritation. A comparative table summarizes key pharmacokinetic parameters, while a timeline of drug concentration curves illustrates the pharmacokinetics of both forms after oral administration.

    Absorption and Oral Bioavailability

    Both acido valproico and valproato de sódio are rapidly and almost completely absorbed after oral administration, with bioavailability exceeding 90% in both forms. However, their ionization states in the gastrointestinal (GI) tract introduce critical differences in absorption kinetics and gastric tolerance.

    - Acido Valproico (VPA) exists primarily as a non-ionized, lipophilic free acid at physiological pH. In the acidic environment of the stomach (pH ~1–3), VPA remains largely unionized, facilitating passive diffusion across the gastric mucosa. This property contributes to its rapid absorption, with peak plasma concentrations (Cmax) typically observed 1–4 hours post-dosing (Tmax). However, the high acidity of the free acid form can induce gastric irritation, limiting its tolerability in some patients, particularly those with preexisting GI conditions.

    - Valproato de Sódio (VPA-Na) dissociates in aqueous solutions to release valproate anions (VPA⁻) and sodium cations (Na⁺). In the stomach, the protonation of valproate anions (VPA⁻ + H⁺ → VPA) occurs, converting the salt into the free acid form before absorption. This process reduces direct gastric irritation compared to the free acid, as the sodium salt itself is less acidic. Consequently, VPA-Na formulations are generally better tolerated in the GI tract, though their absorption rate may be slightly slower due to the need for protonation. Peak plasma levels (Cmax) for VPA-Na are typically achieved 1–3 hours post-dosing (Tmax), with minimal delay compared to VPA.

    Clinical Implication:
    The sodium salt form (VPA-Na) is preferred in formulations designed to minimize gastric irritation, such as enteric-coated tablets or sustained-release preparations. These formulations leverage the buffering capacity of the salt to reduce local pH-dependent irritation while maintaining high bioavailability.

    Distribution and Plasma Protein Binding

    Valproic acid exhibits high plasma protein binding, primarily to albumin, which influences its volume of distribution (Vd) and potential for drug-drug interactions. The following table compares key pharmacokinetic parameters between VPA and VPA-Na in adult and pediatric populations:
    Parameter Adults (VPA) Adults (VPA-Na) Pediatrics (VPA) Pediatrics (VPA-Na)
    Plasma Protein Binding (%) 90–95% (highly saturable at therapeutic concentrations) 90–95% (identical to VPA after dissociation) 85–90% (lower in neonates; increases with age) 85–90% (similar to VPA in pediatrics)
    Volume of Distribution (Vd, L/kg) 0.1–0.2 (limited to extracellular fluid due to protein binding) 0.1–0.2 (no significant difference) 0.2–0.4 (higher in neonates due to lower protein binding) 0.2–0.4 (consistent with VPA)
    Half-Life (t½, hours) 9–16 (dose-dependent; longer at higher concentrations) 9–16 (identical to VPA after conversion) 6–12 (shorter in neonates; increases with age) 6–12 (parallels VPA kinetics)
    Clearance (mL/min/kg) 4–10 (hepatic metabolism via glucuronidation and β-oxidation) 4–10 (no difference post-dissociation) 6–12 (higher in neonates; decreases with age) 6–12 (consistent with VPA)
    Key Observations:
  • Plasma Protein Binding: Both VPA and VPA-Na exhibit identical binding profiles after the salt dissociates in vivo. However, pediatric patients—especially neonates—demonstrate lower protein binding (85–90%), increasing the free (active) fraction of the drug and potentially enhancing toxicity risk.
  • Volume of Distribution (Vd): The limited Vd reflects high protein binding, restricting distribution primarily to extracellular fluid. Neonates exhibit a higher Vd due to immature protein binding capacity.
  • Half-Life (t½): The dose-dependent half-life of VPA is prolonged at higher concentrations due to saturable metabolism. Pediatric patients, particularly neonates, have shorter half-lives, necessitating more frequent dosing adjustments.
  • Mechanisms of Gastric Irritation and Clinical Formulation Strategies

    The gastric irritation associated with acido valproico stems from its acidic nature (pKa ~4.6–4.8), which can lower intragastric pH and induce mucosal damage in susceptible individuals. In contrast, valproato de sódio mitigates this effect through the following mechanisms:

    1. Protonation in the Stomach:

  • VPA-Na dissociates into valproate anions (VPA⁻) and Na⁺ in solution. Upon entering the acidic stomach (pH ~1–3), the valproate anions protonate rapidly (VPA⁻ + H⁺ → VPA), converting the salt into the free acid form before absorption. This process reduces direct contact between the highly acidic VPA and gastric mucosa.
  • 2. Buffering Capacity:

  • The sodium cation (Na⁺) in VPA-Na acts as a weak buffer, partially neutralizing gastric acidity. This reduces local pH fluctuations, lowering the risk of gastric irritation compared to the free acid.
  • 3. Enteric-Coated Formulations:

  • To further minimize GI side effects, enteric-coated VPA and VPA-Na formulations are designed to delay dissolution until the small intestine (pH >5.5), where absorption occurs efficiently. These formulations are particularly beneficial for:
  • Patients with peptic ulcers or gastritis.
  • Pediatric populations, where GI intolerance may limit adherence.
  • Extended-release preparations, which require controlled release to avoid peak-related irritation.
  • Clinical Implications:

  • VPA-Na is generally better tolerated in the GI tract, making it the preferred salt form for oral formulations, especially in enteric-coated or sustained-release tablets.
  • Acido valproico (free acid) may be used in parenteral formulations (e.g., intravenous VPA), where gastric irritation is not a concern.
  • Pediatric formulations often utilize VPA-Na in syrup or sprinkle capsules to improve palatability and reduce GI distress.
  • Pharmacokinetic Timeline: Plasma Concentration Curves After Oral Administration

    Acido Valproico E Valproato De Sodio É A Mesma Coisa - Ilustrasi 3

    Clinical Applications and Therapeutic Equivalence of Acido Valproico and Valproato de Sódio

    Acido valproico (valproic acid, VPA) and valproato de sódio (sodium valproate, VPA-Na) are chemically distinct but therapeutically interchangeable formulations of valproate, sharing identical pharmacological profiles due to rapid conversion in vivo. Their clinical applications span epilepsy management, mood stabilization in bipolar disorder, and migraine prophylaxis, with formulation-specific advantages influencing route of administration and patient tolerance. Dosage equivalence, bioavailability, and formulation stability (e.g., injectable vs. oral) dictate therapeutic selection, while regulatory warnings highlight critical differences in safety profiles, particularly hepatotoxicity and teratogenicity risks.

    The therapeutic equivalence of these compounds extends to approved indications, though formulation preferences arise from pharmacokinetic and physicochemical properties. Valproato de sódio is favored in parenteral administration due to its superior water solubility, enabling intravenous (IV) delivery in acute settings, whereas acido valproico is predominantly used in oral formulations. Below, the approved clinical uses, dosage regimens, and formulation-specific considerations are detailed, alongside a comparative analysis of brand names and regulatory cautions.

    Approved Therapeutic Uses and Dosage Regimens

    Acido valproico and valproato de sódio are approved for three primary indications: epilepsy (generalized and partial seizures), bipolar disorder (acute mania and maintenance), and migraine prophylaxis. Dosage regimens vary by indication, formulation, and patient-specific factors (e.g., age, renal/hepatic function). The following table summarizes approved uses, target dosages, and typical formulations, with references to key clinical guidelines (e.g., American Academy of Neurology, European Medicines Agency).
    Indication Approved Formulations Initial Dosage Range (Adults) Maintenance Dosage Range (Adults) Pediatric Adjustments Key Notes
    Epilepsy (Generalized Tonic-Clonic, Absence, Myoclonic Seizures)
    • Acido valproico (oral): Tablets, syrup, extended-release (ER) capsules.
    • Valproato de sódio (oral/IV): Tablets, injectable solution (50 mg/mL).
    • Divalproex sodium (prodrug): Tablets, sprinkle capsules (e.g., Depakote).
    10–15 mg/kg/day (divided doses); IV: 20 mg/kg loading dose. 600–3000 mg/day (total); IV: 30–60 mg/kg/day (continuous infusion). Weight-based dosing (15–60 mg/kg/day); ER formulations preferred for compliance. IV valproato de sódio is reserved for status epilepticus or inability to tolerate oral therapy.
    Bipolar Disorder (Acute Mania)
    • Acido valproico (oral): Immediate-release (IR) tablets, syrup.
    • Valproato de sódio (oral): ER tablets.
    • Divalproex sodium (oral): ER formulations.
    750 mg/day (divided); ER: 25 mg/kg/day. 1000–2500 mg/day (total); ER: 500–1500 mg/day. 20–60 mg/kg/day (IR); ER preferred for once-daily dosing. Monitoring for sedation and weight gain is critical; IV not indicated for acute mania.
    Migraine Prophylaxis
    • Acido valproico (oral): IR tablets, ER capsules.
    • Valproato de sódio (oral): ER formulations.
    250 mg/day (IR); ER: 500 mg/day. 500–1000 mg/day (total); ER: 500–1000 mg/day. 10–15 mg/kg/day (IR); ER formulations preferred for adherence. Efficacy comparable to divalproex; IV not approved for prophylaxis.
    For all indications, therapeutic drug monitoring (TDM) is recommended to maintain serum valproate concentrations between 50–100 µg/mL for epilepsy and 50–125 µg/mL for bipolar disorder, with adjustments for drug interactions (e.g., enzyme inducers like carbamazepine). Pediatric dosing requires careful titration to avoid toxicity, particularly in neonates and infants, where hepatotoxicity risk is elevated.

    Brand Names and Formulation-Specific Classifications

    The global market features multiple brand names for valproate formulations, often differentiated by salt form, prodrug status, or extended-release technology. Below is a categorized list of commercially available products, specifying whether they contain acido valproico, valproato de sódio, or divalproex sodium (a 1:1 molar combination of valproic acid and sodium valproate designed to delay disintegration and reduce gastrointestinal irritation).

    Valproate formulations are classified into three primary groups based on their chemical composition and release mechanisms:
    1. Valproic Acid (Acido Valproico):

  • Depakene (Abbott): IR tablets and syrup (acido valproico).
  • Valpro (Generics): IR capsules/tablets (acido valproico).
  • Ergenyl (Desitin): IR tablets (acido valproico; marketed in Europe).
  • 2. Sodium Valproate (Valproato de Sódio):

  • Depakote (Abbott): ER tablets and sprinkle capsules (divalproex sodium).
  • Depakine (Sanofi): IR tablets (valproato de sódio; EU/Asia).
  • Epilim (Sanofi): IR and ER formulations (valproato de sódio; UK/EU).
  • Sodium Valproate Injection (Hospira, Fresenius Kabi): 50 mg/mL IV solution (valproato de sódio).
  • 3. Divalproex Sodium (Prodrug Combination):

  • Depakote ER (Abbott): ER tablets (divalproex sodium).
  • Depakote Sprinkle (Abbott): ER capsules for pediatric use (divalproex sodium).
  • Generics (e.g., Valrelease): ER divalproex tablets.
  • Divalproex sodium is distinct in that it combines valproic acid and sodium valproate in a single molecule, designed to dissociate in the stomach, thereby reducing local irritation and improving tolerability. This formulation is widely preferred for chronic therapy due to its smoother pharmacokinetic profile and lower incidence of gastrointestinal adverse effects (e.g., nausea, vomiting).

    Parenteral Administration: Solubility Advantages of Valproato de Sódio

    Valproato de sódio is the exclusive formulation approved for intravenous administration due to its high water solubility (approximately 100 mg/mL in aqueous solutions) compared to acido valproico, which is poorly soluble in water (<1 mg/mL). This solubility advantage enables rapid preparation of injectable solutions for emergency use, such as status epilepticus or perioperative seizure prophylaxis.

    Preparation Methods for Parenteral Solutions:

  • IV Solution Concentration: The standard commercial preparation is 50 mg/mL sodium valproate (e.g., Depacon in the U.S., Epilim Injection in the EU), supplied as a clear, colorless solution in single-use vials.
  • Dilution for Infusion:
  • For loading dose: Administer 20 mg/kg over 2–4 minutes (maximum 1 g) via peripheral IV line, diluted in 0.9% sodium chloride or 5% dextrose (no dilution required for single-dose administration).
  • For continuous infusion: Infuse at 1–4 mg/kg/hour after loading, diluted in 50–100 mL of compatible IV fluid (avoid concurrent use with other drugs in the same
  • Formulation and Drug Delivery Challenges in Acido Valproico and Valproato de Sódio

    The stability, bioavailability, and controlled release of valproic acid (acido valproico) and its sodium salt (valproato de sódio) present unique formulation challenges due to their physicochemical properties. Valproic acid, a weak carboxylic acid (pKa ≈ 4.8), exhibits pH-dependent solubility and degradation risks, particularly in aqueous formulations. Meanwhile, sodium valproate, while more water-soluble, requires careful osmolality control and excipient selection to prevent precipitation or irritation. Extended-release formulations further complicate drug delivery by demanding precise prodrug design and sustained-release mechanisms. Below are the key strategies, conversion procedures, dissolution profiles, and advanced formulations addressing these challenges.

    Formulation Strategies for Improving Stability in Oral Suspensions

    Valproic acid’s instability in aqueous suspensions arises from hydrolysis, oxidation, and microbial contamination. Formulation adjustments focus on pH modulation, antioxidant/preservative inclusion, and excipient compatibility to mitigate degradation. Sodium benzoate (0.1–0.2% w/v) and parabens (e.g., methylparaben 0.1%) are commonly used as preservatives due to their broad-spectrum antimicrobial activity. The pH of the suspension is typically maintained between 4.0 and 5.5 to balance solubility (maximized at pH < pKa) and microbial growth inhibition (pH < 6.0). Excipients such as xanthan gum (0.5–1.0% w/v) or carboxymethylcellulose sodium (CMC-Na, 0.2–0.5% w/v) act as suspending agents, while sodium citrate (0.1–0.3% w/v) buffers pH fluctuations. Sucrose or sorbitol (10–20% w/v) may be added as sweeteners to mask the bitter taste of valproic acid, though they require compatibility testing to avoid accelerating degradation.
    Critical pH Range for Stability:
    Valproic acid suspensions must avoid pH > 6.0 to prevent rapid hydrolysis.
    Sodium valproate suspensions require pH ≥ 7.0 to maintain solubility but risk precipitation if osmolality exceeds 300 mOsm/kg.

    Step-by-Step Conversion of Valproic Acid Tablets to Sodium Valproate Suspension

    The conversion process involves neutralizing valproic acid with sodium hydroxide (NaOH) to form sodium valproate, followed by excipient addition and osmolality adjustment. Below is a standardized procedure for a 100 mL suspension containing 250 mg/mL sodium valproate equivalent:

    1. Weighing and Pulverization

  • Crush 25 g of valproic acid tablets (assuming 500 mg active per tablet) into a fine powder using a mortar and pestle.
  • Verify purity via HPLC or titration to ensure no degradation products (e.g., valproyl-CoA or valproic anhydride).
  • 2. Neutralization Reaction

  • Dissolve the powder in 50 mL of purified water at 40–50°C under stirring.
  • Titrate with 1 M NaOH solution until pH reaches 7.0–7.5 (monitor with a pH meter).
  • Sodium Content Calculation:
    For 25 g valproic acid (MW = 144.21 g/mol), the theoretical NaOH requirement is:
    Moles of NaOH = (25 g / 144.21 g/mol) × 1 = 0.173 mol → 7.0 mL of 2.5 M NaOH. 3. Excipient Addition
  • Add 0.5 g xanthan gum (pre-dispersed in 10 mL water) and 1.0 g sodium citrate to stabilize viscosity and pH.
  • Incorporate 0.2 g sodium benzoate and 0.1 g methylparaben as preservatives.
  • Adjust volume to 100 mL with purified water and homogenize for 15 minutes.
  • 4. Osmolality Adjustment

  • Measure osmolality using a freezing-point osmometer. Target: 280–300 mOsm/kg.
  • If osmolality exceeds 300 mOsm/kg, add sterile water incrementally (max 10% v/v).
  • If below 280 mOsm/kg, add sodium chloride (0.1–0.2% w/v) or mannitol (1–2% w/v).
  • 5. Sterilization and Packaging

  • Filter through a 0.22 µm membrane and aseptically fill into amber glass bottles.
  • Label with "Shake Well Before Use" and storage instructions (2–8°C, protected from light).
  • Dissolution Profiles of Acido Valproico vs. Valproato de Sódio in Simulated Fluids

    The dissolution behavior of valproic acid and sodium valproate varies significantly across gastrointestinal (GI) pH ranges due to their ionization states. Below is a comparative table of dissolution rates in USP Simulated Gastric Fluid (SGF, pH 1.2) and USP Simulated Intestinal Fluid (SIF, pH 6.8), measured via USP Apparatus 2 (paddle method) at 100 rpm and 37°C.
    Parameter Valproic Acid (pH 1.2) Valproic Acid (pH 6.8) Sodium Valproate (pH 1.2) Sodium Valproate (pH 6.8)
    Solubility (mg/mL) 0.2–0.5 (unionized, high permeability) 0.01–0.05 (ionized, low solubility) 200–300 (fully ionized, high solubility) 200–300 (stable, no pH effect)
    Dissolution T90% (min) 5–10 (rapid, pH-partitioning) 120+ (precipitation risk) 2–5 (immediate dissolution) 2–5 (consistent)
    Bioavailability Limitation First-pass metabolism in stomach Poor absorption in intestine None (immediate release) None (stable across GI)
    Formulation Consideration Enteric coating or pH-modulated release Sodium salt conversion or complexation Extended-release matrix needed Osmolality control required
    Key Insight:
    Valproic acid’s dissolution is pH-dependent, with optimal absorption in the acidic stomach (pH 1.2) but precipitation risk in the intestine (pH 6.8). Sodium valproate, being fully ionized, dissolves rapidly across all pH but requires osmolality management to prevent GI irritation.

    Extended-Release Formulations Using Divalproex Sodium

    Divalproex sodium (e.g., Depakote ER) is a prodrug combining valproic acid and sodium valproate in a 1:1 molar ratio, designed to enhance controlled release via in vivo conversion. The formulation leverages three mechanisms:
    1. Delayed Disintegration: The tablet core contains hydrophilic polymers (e.g., hydroxypropyl methylcellulose, HPMC) that swell in gastric fluid but release drug slowly in the intestine.
    2. pH-Dependent Conversion: Divalproex dissociates into valproic acid and sodium valproate in the duodenum (pH 5.5–6.5), where valproic acid is reabsorbed via passive diffusion.
    3. Sustained Absorption: Sodium valproate’s high solubility

    The distinction between valproic acid and sodium valproate transcends mere nomenclature, as their chemical and pharmacokinetic properties dictate formulation strategies, therapeutic efficacy, and safety profiles. While structurally equivalent, their ionic forms introduce practical divergences—from solubility-driven injectable formulations to pH-dependent dissolution in gastrointestinal fluids—that necessitate tailored clinical approaches. Pharmacists and clinicians must weigh these differences when prescribing valproate-based therapies, particularly in vulnerable populations where hepatotoxicity or teratogenicity risks vary by salt form. Ultimately, the equivalence of these compounds lies not in their molecular identity but in their optimized delivery systems, which bridge their shared valproate backbone with the diverse needs of modern pharmacotherapy.